Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The com
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Corporation. (NYSE:MCK ) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Br
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compar
McKesson (MCK) came out with quarterly earnings of $8.03 per share, missing the Zacks Consensus Estimate of $8.04 per share. This compares to earnings of $7.74 per share a year ago.

McKesson misses third-quarter revenue estimates

06:05pm, Wednesday, 05'th Feb 2025
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.

McKesson Exceeds EPS, Q3 Profit Surges

05:33pm, Wednesday, 05'th Feb 2025
Healthcare distribution and services specialist McKesson (MCK 0.59%) reported mixed financial results for fiscal 2025's third quarter on Wednesday, Feb. 5. McKesson beat earnings expectations with an
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
In the closing of the recent trading day, McKesson (MCK) stood at $594.75, denoting a -1.63% change from the preceding trading day.
Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics

McKesson Corporation Declares Quarterly Dividend

08:00am, Thursday, 30'th Jan 2025
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on A
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE